TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27014884

Group type: EXPERIMENTAL
Intervention: Type D personality group
Number of subjects: 388

Group type: COMPARATOR
Intervention: Social inhibition group
Number of subjects: 388

Group type: COMPARATOR
Intervention: Group without negative affectivity and social inhibition
Number of subjects: 388

Group type: COMPARATOR
Intervention: Negative affectivity group
Number of subjects: 388
Study: 25042773

Group type: EXPERIMENTAL
Intervention: Self-reported weights (n=191)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Self-reported weights
Number of subjects: 277
Study: 22029714

Group type: EXPERIMENTAL
Intervention: B‐MICS
Number of subjects: 40

Group type: COMPARATOR
Intervention: C‐MICS
Number of subjects: 40
Study: 20858857

Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid-based therapy (in 155 patients with M3V)
Number of subjects: 155

Group type: COMPARATOR
Intervention: All-trans retinoic acid-based therapy (in 748 patients with classical M3)
Number of subjects: 155
Study: 18511608

Group type: EXPERIMENTAL
Intervention: Adding Qa surveillance to monitoring (Flow)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control
Number of subjects: 159
Study: 16389183

Group type: EXPERIMENTAL
Intervention: Sequential BCG and electromotive mitomycin
Number of subjects: 212

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 212
Study: 12375295

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Postural orthotic
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 10355866

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 12 weeks
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment after placebo for long-term
Number of subjects: 31
Study: 7486296

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) transfusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PRP transfusion)
Number of subjects: 20
Study: 1778534

Group type: EXPERIMENTAL
Intervention: 0.05% halometasone cream
Number of subjects: 165

Group type: COMPARATOR
Intervention: 0.25% prednicarbate cream
Number of subjects: 165
Study: 6183898

Group type: EXPERIMENTAL
Intervention: Oral D-penicillamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 9
Study: 31384071

Group type: EXPERIMENTAL
Intervention: Community-led total sanitation campaign (2006)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control villages
Number of subjects: 1000
Study: 29782224

Group type: EXPERIMENTAL
Intervention: Dupilumab (300 mg every 2 weeks for 24 weeks)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 210
Study: 27216328

Group type: EXPERIMENTAL
Intervention: Combined cognitive‐behavioural group interventions (Baghira group training and Positive Parenting Program Triple P)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 42
Study: 24581894

Group type: EXPERIMENTAL
Intervention: Shortened form of problem-solving therapy focusing on caregiver burden
Number of subjects: 140

Group type: COMPARATOR
Intervention: Educational intervention focusing on respiratory diseases (Control Group)
Number of subjects: 140
Study: 22149151

Group type: EXPERIMENTAL
Intervention: Controlled-release aceclofenac 200 mg od (Clanza CR®)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Immediate-release aceclofenac 100 mg bid (Airtal®)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Controlled-release aceclofenac 200 mg od (Clanza CR®) fed state
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Controlled-release aceclofenac 200 mg od (Clanza CR®) fasted state
Number of subjects: 41
Study: 20228982

Group type: EXPERIMENTAL
Intervention: Core Max II without total-etch adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Core Max II with total-etch adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 cement without self-etch adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 cement with self-etch adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Core Max II with adhesive
Number of subjects: 60

Group type: COMPARATOR
Intervention: Core Max II without adhesive
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Panavia F2.0 with adhesive
Number of subjects: 60
Study: 17137844

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 102
Study: 16039293

Group type: EXPERIMENTAL
Intervention: 17beta-estradiol 1mg daily
Number of subjects: 180
Study: 11966505

Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg b.d.
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Mosapride 10 mg b.d.
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Mosapride 7.5 mg t.d.s.
Number of subjects: 566

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study: 9603592

Group type: EXPERIMENTAL
Intervention: Controlled hypotension with mild hemodilution (Group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controlled hypotension with moderate hemodilution (Group B)
Number of subjects: 30
Study: 8065590

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (3.75 mg/monthly)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Danazol (600 mg/daily)
Number of subjects: 50
Study: 2967780

Group type: EXPERIMENTAL
Intervention: Tizanidine (4 mg three times daily)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 31628887

Group type: EXPERIMENTAL
Intervention: Patient counselling covering asthma knowledge, control, adherence to treatment and inhalation techniques
Number of subjects: 192
Study: 29342210

Group type: EXPERIMENTAL
Intervention: Theory of Mind Performance Training (ToMPT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Social Skills Training (SST)
Number of subjects: 49
Study: 26661992

Group type: EXPERIMENTAL
Intervention: Hot water immersion (HWI) at 40 °C for 40 min after exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Thermoneutral immersion (CON) at 34 °C for 40 min after exercise
Number of subjects: 17
Study: 25300460

Group type: EXPERIMENTAL
Intervention: Nilvadipine (8 mg overencapsulated, sustained release capsule)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo (matching overencapsulated sugar pill)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Nilvadipine
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 22791756

Group type: EXPERIMENTAL
Intervention: T gel 10 g + NES gel 8 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: T gel 10 g + NES gel 12 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: T gel 10 g + NES 0 mg (placebo)
Number of subjects: 99
Study: 20406959

Group type: EXPERIMENTAL
Intervention: Solid-organ transplantation
Number of subjects: 83016
Study: 18195264

Group type: EXPERIMENTAL
Intervention: MRI measures (ventricular volumes)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: MRI measures (hippocampal volumes)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Clinical variables (including Delayed 10‐word list recall, New York University Delayed Paragraph Recall, Alzheimer's Disease Assessment Scale‐Cognitive Subscale total score)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Cognitive measures alone
Number of subjects: 129
Study: 15647077

Group type: EXPERIMENTAL
Intervention: gamolenic acid (GLA) and antioxidants
Number of subjects: 555

Group type: COMPARATOR
Intervention: placebo fatty acids and antioxidants
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: GLA and placebo antioxidants
Number of subjects: 555

Group type: COMPARATOR
Intervention: placebo fatty acids and placebo antioxidants
Number of subjects: 555
Study: 15029131

Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 62
Study: 10943754

Group type: EXPERIMENTAL
Intervention: Isometric shoulder strength training
Number of subjects: 69

Group type: COMPARATOR
Intervention: Isometric shoulder endurance training
Number of subjects: 69
Study: 9028785

Group type: EXPERIMENTAL
Intervention: Vision condition
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Nonvision condition
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Two-process, random-walk model
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ornstein-Uhlenbeck model
Number of subjects: 3
Study: 8498757

Group type: EXPERIMENTAL
Intervention: Endoscopic ligation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy
Number of subjects: 77
Study: 3088641

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum during the withdrawal period
Number of subjects: 25

Group type: COMPARATOR
Intervention: No nicotine replacement
Number of subjects: 25
Study: 2519530

Group type: EXPERIMENTAL
Intervention: Prednisone (60 mg per day, tapered to 20 mg per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cyclosporine (7.5 mg per kilogram of body weight per day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of cyclosporine and low dose prednisone
Number of subjects: 36
Study: 31727538

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily until PSA progression followed by enzalutamide 160 mg orally once daily (group A)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Enzalutamide 160 mg orally once daily (as second-line therapy after abiraterone)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Abiraterone acetate 1000 mg orally once daily plus prednisone 5 mg orally twice daily (as second-line therapy after enzalutamide)
Number of subjects: 202
Study: 28000425

Group type: EXPERIMENTAL
Intervention: Active procedure (pose™ procedure)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 332
Study: 25802954

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 10 Hz
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation at 80 Hz
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham (presence of electrodes without stimulation)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (no electrodes)
Number of subjects: 15
Study: 23339811

Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 300

Group type: COMPARATOR
Intervention: TAXUS paclitaxel‐eluting stent (PES)
Number of subjects: 300
Study: 21606834

Group type: EXPERIMENTAL
Intervention: Stress-shielding polymer
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Stress shielding of swine incisions
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control and elevated stress states
Number of subjects: 9
Study: 19917955

Group type: EXPERIMENTAL
Intervention: Alefacept for 12 consecutive weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 16697728

Group type: EXPERIMENTAL
Intervention: Distal splenorenal shunt (DSRS)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Transjugular intrahepatic portal systemic shunt (TIPS)
Number of subjects: 140
Study: 15725969

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.6 mg/kg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 11159149

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9424900

Group type: EXPERIMENTAL
Intervention: Quadruple therapy
Number of subjects: 0
Study: 7951706

Group type: EXPERIMENTAL
Intervention: 6-day casting period
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3-day casting period
Number of subjects: 15
Study: 2439457

Group type: EXPERIMENTAL
Intervention: 10% dextran 40 (n = 8)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch 200/0.5 (n = 10)
Number of subjects: 18
Study: 29661195

Group type: EXPERIMENTAL
Intervention: Guideline development group with patient representatives
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline development group without patient representatives
Number of subjects: 0
Study: 28439352

Group type: EXPERIMENTAL
Intervention: Preoperative practice with instructor feedback (PPF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Preoperative practice alone (PP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Feedback alone (F)
Number of subjects: 18
Study: 26254706

Group type: EXPERIMENTAL
Intervention: Beta2-microglobulin >1.92 mg/L
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: C-peptide <1.32 ng/ml
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: C-peptide <2.22 ng/ml
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: High-density lipoprotein (HDL)
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: Transferrin
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: History of angina pectoris
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: HDL
Number of subjects: 697
Study: 23714781

Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 1368
Study: 21395656

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19033149

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (CBT)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Internet-based problem solving therapy (PST)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Waiting list control (WL)
Number of subjects: 263
Study: 17153820

Group type: EXPERIMENTAL
Intervention: Priority mail
Number of subjects: 260

Group type: COMPARATOR
Intervention: First-Class mail
Number of subjects: 260
Study: 14610160

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: Valsartan plus captopril
Number of subjects: 14703

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14703

Group type: EXPERIMENTAL
Intervention: Valsartan and captopril
Number of subjects: 14703
Study: 10705068

Group type: EXPERIMENTAL
Intervention: Home-based asthma health education session
Number of subjects: 40

Group type: COMPARATOR
Intervention: Booklet representing conventional care
Number of subjects: 40
Study: 8856613

Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination (10, 30, 100, and 300 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination (100 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination (300 micrograms)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: V beta 17 peptide vaccination
Number of subjects: 15
Study: 1794215

Group type: EXPERIMENTAL
Intervention: Captopril monotherapy
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide (HCTZ)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Metoprolol and/or Hydrochlorothiazide (HCTZ)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 91
Study: 6363079

Group type: EXPERIMENTAL
Intervention: Lidoflazine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lidoflazine and propranolol combination
Number of subjects: 24

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 24
Study: 31791416

Group type: EXPERIMENTAL
Intervention: Tennant Biomodulator
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional Chinese acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 100
Study: 29233196

Group type: EXPERIMENTAL
Intervention: Media Smart-Targeted (MS-T)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Student Bodies (SB)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control
Number of subjects: 575
Study: 27289105

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Control group (regular visit with midwife/social worker)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 1051
Study: 23466193

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with essential oil (AT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oil massage without essential oil (OT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 63
Study: 22727431

Group type: EXPERIMENTAL
Intervention: Adaptive servo ventilation (ASV)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-ASV treatment
Number of subjects: 22
Study: 20634298

Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 102

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 102
Study: 18076864

Group type: EXPERIMENTAL
Intervention: TiF(4) solution applied (ERO+F)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No treatment (ERO+no-F)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TiF(4) only (no-ERO+F)
Number of subjects: 10
Study: 16004704

Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine (ASP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) alone
Number of subjects: 60
Study: 11841884

Group type: EXPERIMENTAL
Intervention: Verapamil infusion at a rate of 1 mg/min to a maximum of 20 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Diltiazem infusion at a rate of 2.5 mg/min to a maximum of 50 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Verapamil infusion
Number of subjects: 161

Group type: COMPARATOR
Intervention: Diltiazem infusion
Number of subjects: 161
Study: 9951214

Group type: EXPERIMENTAL
Intervention: ICD-10 hyperkinetic disorder and DSM-IV ADHD (n=21)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: ADHD only (n=22)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Clinic control (n=15)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Normal control (n=19)
Number of subjects: 77
Study: 7772352

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope with newly developed mask adapter (Group FI)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (Group L)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laryngeal mask airway (Group LMA)
Number of subjects: 30
Study: 2286469

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrofurantoin (200 mg per day for one week)
Number of subjects: 0
Study: 323118

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Atropine 2-4 mg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day and Atropine 2-4 mg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31163975

Group type: EXPERIMENTAL
Intervention: Syndemic factors (e.g., polydrug use, hazardous alcohol consumption, client‐perpetrated violence, depression, and sexually transmitted infections)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Three syndemic factors
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Four or five syndemic factors
Number of subjects: 295
Study: 31300264

Group type: EXPERIMENTAL
Intervention: Caloric vestibular stimulation (CVS) via a portable device, self-administered twice daily for 8 weeks.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment (no specific details provided).
Number of subjects: 33
Study: 28961838

Group type: EXPERIMENTAL
Intervention: R-CHOP administered every 14 days with CNS prophylaxis (IT methotrexate)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: R-CHOP administered every 21 days with CNS prophylaxis (IT methotrexate)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: CNS prophylaxis (IT methotrexate)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: CNS-IPI high-risk group (4-6 risk factors)
Number of subjects: 1080
Study: 24932945

Group type: EXPERIMENTAL
Intervention: Hair testing for marijuana
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hair testing for cocaine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hair testing for amphetamines
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Hair testing for opioids
Number of subjects: 360

Group type: COMPARATOR
Intervention: Self-reported drug use
Number of subjects: 360
Study: 24349541

Group type: EXPERIMENTAL
Intervention: Patient self-reported risk factors including body mass index, knee pain, previous knee replacement, and analgesia use for joint pain.
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: 5-variable predictive model based on self-reported risk factors.
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: WOMAC weighted score for knee pain assessment.
Number of subjects: 1462
Study: 20006198

Group type: EXPERIMENTAL
Intervention: Use of metal stylet
Number of subjects: 80

Group type: COMPARATOR
Intervention: No stylet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall assessment (both groups)
Number of subjects: 80
Study: 18778385

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Drug Information and Advice (Control)
Number of subjects: 326
Study: 16914772

Group type: EXPERIMENTAL
Intervention: autologous fibrin tissue adhesive (auto‐FTA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: control group (standard treatment alone)
Number of subjects: 100
Study: 12809330

Group type: EXPERIMENTAL
Intervention: Heptavalent conjugate vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugate vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10894286

Group type: EXPERIMENTAL
Intervention: famciclovir 500 mg twice a day
Number of subjects: 293

Group type: COMPARATOR
Intervention: acyclovir 400 mg five times a day
Number of subjects: 293